Key2Brain
Key2Brain is a Swedish biotechnology company committed to improving the lives of individuals affected by severe diseases related to the brain.
Key2Brain is a Swedish biotechnology company committed to improving the lives of individuals affected by severe diseases related to the brain.
AnaCardio AB is a privately held Swedish, clinical stage biopharmaceutical company developing novel drugs to treat heart failure.
Prolevi’s long term vision is to treat metabolic disorders deploying our platform patent pending technology. They personalize the formulations in synergy with circadian rhythm.
Fluicell is an innovative life science company dedicated to delivering single-cell microfluidic research tools and services for scientists worldwide, based in Gothenburg Sweden.
Modus Therapeutics is a Swedish biotech company developing sevuparin for diseases with high unmet medical need. The Company’s focus is to develop sevuparin for patients with sepsis/septic shock, a severe and often fatal condition.
One-carbon Therapeutics AB is a clinical-stage biotechnology company headquartered in Sweden, pioneering novel anti-cancer therapies. Their most advanced candidate - TH9619 - has started clinical development in 2025.
Strike Pharma is using the company’s proprietary Adaptable Drug Affinity Conjugate (ADAC) technology to take precision medicine to a new level, enabling development of truly individualized immunotherapeutic treatments based on the genetic profile of each patient’s tumor.
QPS is a GLP/GCP-compliant clinical research organization (CRO) delivering the highest grade of discovery, preclinical, and clinical drug development services.
Merck is a global science and technology company, their purpose is to solve the toughest problems in life science by collaborating with the global scientific community – and through that, they aim to accelerate access to better health for people everywhere.
PharmaLex is now part of Cencora, a leading global pharmaceutical solutions organization centered on improving lives around the world.